Table 1.

Timepoints of outcome assessments in the included trials [27–31]

Study name	Intervention	Timepoint 1	Timepoint 2	Timepoint 3	Timepoint 4	Timepoint 5	Timepoint 6
Athauda 2017	Exenatide	12 weeks	24 weeks*	36 weeks	48 weeks	60 weeks#	–
Aviles-Olmos 2013	Exenatide	26 weeks*	48 weeks	52 weeks#	56 weeks	–	–
Malatt 2022	Liraglutide	28 weeks*	54 weeks#	–	–	–	–
McGarry 2024	NLY01 2.5, 5 mg	4 weeks	8 weeks	12 weeks	24 weeks*	36 weeks	44 weeks#
Meissner 2024	Lixisenatide	26 weeks*	52 weeks#	–	–	–	–

^*: Timepoints used as midpoints and pooled together

^#: Timepoints used as endpoints and pooled together